AbbVie has achieved real absolute reductions in operational emissions and set science-aligned near-term targets, but withholds Scope 3 totals—critical for a $56B pharma manufacturer. Biodiversity assessment is nascent, and membership in climate-oppositional trade groups remains unexamined. A pattern of $7.57B in regulatory penalties signals deeper governance weaknesses.
Same formula for every company. No curve. No private weighting.
SINK = (0.3 × Base + 0.7 × Performance) × ScaleStrongest on Carbon Footprint — Operations and Targets & Commitments (7/10, 7/10). Weakest on Nature & Biodiversity Impact and Controversies & Red Flags (3/10, 4/10).
11 sources used in this assessment. All publicly available. Each row shows which rubric questions it informed.
If you believe a source has been misread or a newer version exists, submit a challenge.
Among the 11 major healthcare / pharmaceuticals brands we've scored, AbbVie sits 7th of 11.
Score history begins 4 April 2026.
As AbbVie's score updates, the trajectory will appear here.
We're backfilling historical scores for FTSE 100 and S&P 100 companies over the coming weeks.
Every challenge is published. We'd rather be corrected than wrong — that's the whole point.
No challenges submitted yet. If you have evidence that contradicts this score, you can challenge any question above — cite a public source and we'll review it.
AbbVie is a US-headquartered pharmaceutical company founded in 2013 as a spin-off from Abbott Labs. With ~$56B in annual revenue, it manufactures specialty pharmaceuticals, immunology drugs (Humira, Rinvoq), and contract manufacturing services. It ranks mid-tier among large pharma on climate disclosure but lags on supply chain transparency and nature risk.
Peer pharma manufacturer with similar supply chain complexity and regulatory exposure.
View breakdown →Large-cap pharma with stronger Scope 3 disclosure and nature risk assessment practices.
View breakdown →Diversified healthcare conglomerate with more mature circular economy and waste reduction programs.
View breakdown →Comparable pharma company facing similar pricing controversy patterns and governance scrutiny.
View breakdown →Email alerts when a rubric question is verified, a challenge is resolved, or the overall score changes.
One email, every Sunday. Score changes, new research, the stories behind the numbers. Free.
No spam. Unsubscribe in one click.
Readers and institutions support our work. Companies can pay to submit evidence we couldn't find. Neither type of payment changes a score.